| 2026-08-05 | 10-Q | 10.1 | Amended and Restated Non-Employee Director Compensation Policy dated June 24, 2026 |
|---|
| 2026-02-26 | 8-K | 10.1 | Sales Agreement, by and between Kymera Therapeutics, Inc. and TD Securities (USA) LLC, dated February 26, 2026. |
|---|
| 2025-08-11 | 10-Q | 10.3 | Amended and Restated Non-Employee Director Compensation Policy dated June 25, 2025. |
|---|
| 2025-08-11 | 10-Q | 10.2 | Letter between the Registrant and Genzyme Corporation, dated as of April 10, 2025. |
|---|
| 2025-06-27 | 8-K | 10.1 | Registration Rights Agreement among Kymera Therapeutics, Inc. and certain of its stockholders, dated June 26, 2025. |
|---|
| 2025-05-09 | 10-Q | 10.1 | Form of Performance Stock Unit Award Agreement under 2020 Stock Option and Incentive Plan, as amended |
|---|
| 2024-10-31 | 10-Q | 10.2 | Open Market Sale AgreementSM, by and between the Registrant and Jefferies LLC, dated October 31, 2024. |
|---|
| 2024-10-31 | 10-Q | 10.1 | Letter between the Registrant and Genzyme Corporation, dated as of July 31, 2024. |
|---|
| 2024-06-20 | 8-K | 10.1 | Amendment No. 1 to the 2020 Stock Option and Incentive Plan |
|---|
| 2024-05-02 | 10-Q | 10.1 | Amended and Restated Non-Employee Director Compensation Policy dated March 27, 2024. |
|---|
| 2024-02-22 | 10-K | 10.16 | Letter between the Registrant and Genzyme Corporation, dated as of November 14, 2023. |
|---|
| 2024-02-22 | 10-K | 10.13 | Lease between the Registrant and ARE-MA REGION NO. 75, LLC dated as of December 20, 2021. |
|---|
| 2024-02-22 | 10-K | 10.12 | Second Amendment to Master Collaboration Agreement between the Registrant and Vertex Pharmaceuticals Incorporated, dated as of October 21, 2021. |
|---|
| 2024-02-22 | 10-K | 10.10 | Amended and Restated Collaboration and License Agreement between the Registrant and Genzyme Corporation, dated as of November 15, 2022. |
|---|
| 2024-02-22 | 10-K | 10.3 | Amended and Restated Non-Employee Director Compensation Policy dated January 17, 2022. |
|---|
| 2023-02-23 | 10-K | 10.13 | Lease between the Registrant and ARE-MA REGION NO. 75, LLC dated as of December 20, 2021. |
|---|
| 2023-02-23 | 10-K | 10.12 | Second Amendment to Master Collaboration Agreement between the Registrant and Vertex Pharmaceuticals Incorporated, dated as of October 21, 2021. |
|---|
| 2023-02-23 | 10-K | 10.10 | Amended and Restated Collaboration and License Agreement between the Registrant and Genzyme Corporation, dated as of November 15, 2022. |
|---|
| 2023-02-23 | 10-K | 10.3 | Amended and Restated Non-Employee Director Compensation Policy dated January 17, 2022. |
|---|
| 2022-08-19 | 8-K | 10.2 | Registration Rights Agreement, dated August 18, 2022, by and among Kymera Therapeutics, Inc. and the persons party thereto |
|---|
| 2022-08-19 | 8-K | 10.1 | Securities Purchase Agreement, dated August 18, 2022, by and among Kymera Therapeutics, Inc. and the persons party thereto |
|---|
| 2022-02-24 | 10-K | 10.16 | Lease between the Registrant and ARE-MA REGION NO. 75, LLC dated as of December 20, 2021. |
|---|
| 2022-02-24 | 10-K | 10.15 | Second Amendment to Master Collaboration Agreement between the Registrant and Vertex Pharmaceuticals Incorporated, dated as of October 21, 2021. |
|---|
| 2022-02-24 | 10-K | 10.3 | Amended and Restated Non-Employee Director Compensation Policy dated January 17, 2022. |
|---|
| 2020-11-05 | 10-Q | 10.3 | First Amendment to Master Collaboration Agreement between the Registrant and Vertex Pharmaceuticals Incorporated, dated as of August 27, 2020. |
|---|
| 2020-11-05 | 10-Q | 10.2 | First Amendment to Collaboration Agreement between the Registrant and GlaxoSmithKline Intellectual Property Development Limited, dated as of August 27, 2020. |
|---|
| 2020-11-05 | 10-Q | 10.1 | Amended and Restated 2020 Employee Stock Purchase Plan. |
|---|